Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients

Cancer Research

Volumn 66, Issue 17, 2006, Pages 8389-8396

  Tsuruta, Hiroshi ^a   Kishimoto, Hiroyuki ^a   Sasaki, Takehiko ^a   Horie, Yasuo ^a   Natsui, Miyuki ^a   Shibata, Yoshiko ^a   Hamada, Koichi ^a   Yajima, Nobuyuki ^a   Kawahara, Koichi ^a   Sasaki, Masato ^a   Tsuchiya, Norihiko ^a   Enomoto, Katsuhiko ^a   Mak, Tak Wah ^b   Nakano, Toru ^c   Habuchi, Tomonori ^a   Suzuki, Akira ^a  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TORONTO   (Canada)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; MITOGEN ACTIVATED PROTEIN KINASE; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER STAGING; CARCINOMA; CARCINOMA IN SITU; CELL NUCLEUS; CELL PROLIFERATION; CELL SIZE; CELL SURVIVAL; CONTROLLED STUDY; GENE MUTATION; HISTOLOGY; HYPERPLASIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOMA, TRANSITIONAL CELL; CELL NUCLEUS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GENOTYPE; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MICE, KNOCKOUT; MICE, TRANSGENIC; POLYMERASE CHAIN REACTION; PTEN PHOSPHOHYDROLASE; URINARY BLADDER; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 33748999833     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-4627     Document Type: Article

References (50)

1. Messing EM. Urothelial tumors of the urinary tract. In: Walsh PC, editor. Campbell's urology. New York: Saunders; 2002. p. 2732-84.
2. Steinberg GD, Trump DL, Cummings KB. Metastatic bladder cancer. Natural history, clinical course, and consideration for treatment. Urol Clin North Am 1992; 19:735-46.
3. Cappellen D, De Oliveira C, Ricol D, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999;23:18-20.
4. Spruck CH III, Ohneseit PF, Gonzalez-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994;54:784-8.
5. Zhang ZT, Pak J, Shapiro E, Sun TT, Wu XR. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res 1999;59:3512-7.
6. Parsons R, Simpson L. PTEN and cancer. Methods Mol Biol 2003;222:147-66.
7. Maehama T, Dixon JE. The tumor suppressor, PTEN/ MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998;273:13375-8.
8. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655-7.
9. Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/ KDR activation. J Biol Chem 1998;273:30336-43.
10. Gu J, Tamura M, Pankov R, et al. She and FAK differentially regulate cell motility and directionality modulated by PTEN. J Cell Biol 1999;146:389-403.
11. Liu JL, Sheng X, Hortobagyi ZK, et al. Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation. Mol Cell Biol 2005;25:6211-24.
12. Ahn JY, Liu X, Cheng D, et al. Nucleophosmin/B23, a nuclear PI(3,4,5)P(3) receptor, mediates the antiapoptotic actions of NGF by inhibiting CAD. Mol Cell 2005; 18:435-45.
13. Freeman DJ, Li AG, Wei G, et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell 2003;3:117-30.
14. Okumura K, Zhao M, Depinho HA, Furnari FB, Cavenee WK. Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor. Proc Natl Acad Sci U S A 2005;102:2703-6.
15. Suzuki A, de la Pompa JL, Stambolic V, et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 1998;8:1169-78.
16. Liu J, Babaian DC, Liebert M, Steck PA, Kagan J. Inactivation of MMAC1 in bladder transitional-cell carcinoma cell lines and specimens. Mol Carcinog 2000;29:143-50.
17. Wang DS, Rieger-Christ K, Latini JM, et al. Molecular analysis of PTEN and MXI1 in primary bladder carcinoma. Int J Cancer 2000;88:620-5.
18. Aveyard JS, Skilleter A, Habuchi T, Knowles MA. Somatic mutation of PTEN in bladder carcinoma. Br J Cancer 1999;80:904-8.
19. Cairns P, Evron E, Okami K, et al. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene 1998;16:3215-8.
20. Wu X, Obata T, Khan Q, et al. The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. BJU Int 2004;93:143-50.
21. Tanaka M, Koul D, Davies MA, et al. MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells. Oncogene 2000;19:5406-12.
22. Kishimoto H, Hamada K, Saunders M, et al. Physiological functions of Pten in mouse tissues. Cell Struct Funct 2004;28:11-21.
23. Suzuki A, Yamaguchi MT, Ohteki T, et al. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 2001;14:523-34.
24. Saam JR, Gordon JI. Inducible gene knockouts in the small intestinal and colonic epithelium. J Biol Chem 1999;274:38071-82.
25. Shiroyanagi Y, Yamato M, Yamazaki Y, Toma H, Okano T. Urothelium regeneration using viable cultured urothelial cell sheets grafted on demucosalized gastric flaps. BJU Int 2004;93:1069-75.
26. Kim MK, Cho YH, Kim JM, et al. Induction of apoptosis in human leukemia cells by MCS-C2 via caspase-dependent Bid cleavage and cytochrome c release. Cancer Lett 2005;223:239-47.
27. Whiteman DC, Zhou XP, Cummings MC, et al. Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma. Int J Cancer 2002;99:63-7.
28. Hamed S, LaRue H, Hovington H, et al. Accelerated induction of bladder cancer in patched heterozygous mutant mice. Cancer Res 2004;64:1938-42.
29. Horie Y, Suzuki A, Kataoka E, et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 2004;113: 1774-83.
30. Yin H, Leong AS. Histologic grading of noninvasive papillary urothelial tumors: validation of the 1998 WHO/ISUP system by immunophenotyping and follow-up. Am J Clin Pathol 2004;121:679-87.
31. Suzuki A, Kaisho T, Ohishi M, et al. Critical roles of Pten in B cell homeostasis and immunoglobulin class switch recombination. J Exp Med 2003;197:657-67.
32. Paramio JM, Navarro M, Segrelles C, Gomez-Casero E, Jorcano JL. PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein. Oncogene 1999;18:7462-8.
33. Koksal IT, Yasar D, Dirice E, et al. Differential PTEN protein expression profiles in superficial versus invasive bladder cancers. Urol Int 2005;75:102-6.
34. Walker BE. Renewal of cell populations in the female mouse. Am J Anat 1960;107:95-105.
35. Kunze E, Chowaniec J. Pathology of tumours in laboratory animals. Tumours of the rat. Tumours of the urinary bladder. IARC Sci Publ 1990;99:345-97.
36. Ogawa K, Uzvolgyi E, St John MK, et al. Frequent p53 mutations and occasional loss of chromosome 4 in invasive bladder carcinoma induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in B6D2F1 mice. Mol Carcinog 1998;21:70-9.
37. Enomoto T, Ward JM, Perantoni AO. H-ras activation and ras p21 expression in bladder tumors induced in F344/NCr rats by N-butyl-N-(4-hydroxybutyl) nitrosamine. Carcinogenesis 1990;11:2233-8.
38. Min H, Kudo E, Hino A, et al. p53 gene mutation in N-butyl-N-(4- hydroxybutyl)nitrosamine-induced urinary bladder tumors and N-methyl-N- nitrosourea-induced colon tumors of rats. Cancer Lett 1997;117:81-6.
39. Shiina H, Igawa M, Urakami S, et al. Alteration of β and γ-catenin in N-butyl-N-(4-hydroxybutyl)nitrosamine-induced murine bladder cancer. Cancer Res 2001; 61:7101-9.
40. Yoo LI, Liu DW, Le Vu S, et al. Pten deficiency activates distinct downstream signaling pathways in a tissue-specific manner. Cancer Res 2006;66:1929-39.
41. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-7.
42. Lachyankar MB, Sultana N, Schonhoff CM, et al. A role for nuclear PTEN in neuronal differentiation. J Neurosci 2000;20:1404-13.
43. Tanaka K, Horiguchi K, Yoshida T, et al. Evidence that a phosphatidylinositol 3,4,5-trisphosphate-binding protein can function in nucleus. J Biol Chem 1999;274: 3919-22.
44. Logic A, Dunois-Larde C, Rosty C, et al. Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet 2005;14:1153-60.
45. Cheng J, Huang H, Zhang ZT, et al. Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth. Cancer Res 2002;62:4157-63.
46. Zhang ZT, Pak J, Huang HY, et al. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene 2001;20:1973-80.
47. Sibilia M, Fleischmann A, Behrens A, et al. The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development. Cell 2000; 102:211-20.
48. Suzuki A, Itami S, Ohishi M, et al. Keratinocyte-specific Pten deficiency results in epidermal hyperplasia, accelerated hair follicle morphogenesis and tumor formation. Cancer Res 2003;63:674-81.
49. Messing EM. Growth factors and bladder cancer: clinical implications of the interactions between growth factors and their urothehal receptors. Semin Surg Oncol 1992;8:285-92.
50. Thogersen VB, Jorgensen PE, Sorensen BS, et al. Expression of transforming growth factor α and epidermal growth factor receptor in human bladder cancer. Scand J Clin Lab Invest 1999;59:267-77.